Rheumatology

The study objective was to determine if actigraphy could serve as a complementary clinical tool for sleep evaluation in patients with rheumatoid arthritis.

Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis (RA) prescribed a disease-modifying antirheumatic drug (DMARD), until the DMARD kicks in. Test your knowledge of bridging therapy with this quiz.

A personal history rather than a family history of psoriasis is associated with the disease activity and severity of axial joint damage.

Rituximab-arrx is similar in safety and efficacy to rituximab for patients with moderate to severe rheumatoid arthritis.

A recent study, conducted by CreakyJoints, demonstrated that patient-reported satisfaction is affected by both social and cultural norms in Spanish-speaking patients with rheumatoid arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 4, 2022.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."

Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.

Dr. Eliseo Pascual's presentation at EULAR 2022 serves as a reminder to consider gender bias during the diagnosis, treatment, and management of rheumatic diseases.

John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.

Consultation aids can elevate communication around rheumatic and musculoskeletal disease, therefore promoting shared decision making between patients and clinicians.

Massimo Radin, MD, PhD, discusses how low complement levels in the first trimester can predict disease flare in pregnant patients with systemic lupus erythematosus.

Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.

Massimo Radin, MD, PhD, explains how tailoring oral therapy in rheumatoid arthritis, via the TuTOR App, can improve medication adherence.

Bristol Myers Squibb announced positive results from a phase 2 trial that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.

“The role of terminally differentiated T effector memory re-expressing Temra in RA pathogenesis and disease activity is still unclear," investigators stated.

Eliseo Pascual, MD, PhD, discusses sex and gender regarding the diagnosis, treatment, and management of rheumatic disease.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Nicola Luigi Bragazzi, MD, PhD, explains the importance of sex-based medicine in psoriatic arthritis and shares his advice for future studies.

Catch up on Rheumatology Network's top articles of May 2022.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Look back on Rheumatology Network's Congress of Clinical Rheumatology (CCR) East's conference coverage.

COVID-19 has raised additional concerns for rheumatologists, especially regarding health care for patients with rheumatic diseases.

Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.

Anne Winkler, MD, discusses the importance of patient-reported outcome measures when treating her patients with lupus.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.